top of page
Search
  • Writer's picturesiddhesh kapshikar

Recombinant Protein Drug R & D Market, Global Outlook and Forecast 2023-2030

The global Recombinant Protein Drug R & D market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.


This report aims to provide a comprehensive presentation of the global market for Recombinant Protein Drug R & D, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Recombinant Protein Drug R & D. This report contains market size and forecasts of Recombinant Protein Drug R & D in global, including the following market information:


Global Recombinant Protein Drug R & D Market Revenue, 2018-2023, 2024-2030, ($ millions)


Global top five companies in 2022 (%)


The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.

Peptide Hormones Segment to Reach $ Million by 2029, with a % CAGR in next six years.

The global key manufacturers of Recombinant Protein Drug R & D include Eli Lilly, Novo Nordisk, Amgen, Merck, Sanofi, Pfizer, Roche, Gensci and Ankebio, etc. in 2022, the global top five players have a share approximately % in terms of revenue.

We surveyed the Recombinant Protein Drug R & D companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Recombinant Protein Drug R & D Market, by Type, 2018-2023, 2024-2030 ($ millions)

Global Recombinant Protein Drug R & D Market Segment Percentages, by Type, 2022 (%)


  • Peptide Hormones

  • Hematopoietic Factor

  • Cytokines

  • Plasma Protein Factor

  • Recombinase

  • Fusion Protein

  • Other


Global Recombinant Protein Drug R & D Market, by Application, 2018-2023, 2024-2030 ($ millions)

Global Recombinant Protein Drug R & D Market Segment Percentages, by Application, 2022 (%)


  • Diabetes

  • Dwarfism

  • Hemophilia

  • Heart Disease

  • Cancer

  • Other


Global Recombinant Protein Drug R & D Market, By Region and Country, 2018-2023, 2024-2030 ($ Millions)

Global Recombinant Protein Drug R & D Market Segment Percentages, By Region and Country, 2022 (%)


  • North America

  • US

  • Canada

  • Mexico

  • Europe

  • Germany

  • France

  • U.K.

  • Italy

  • Russia

  • Nordic Countries

  • Benelux

  • Rest of Europe

  • Asia

  • China

  • Japan

  • South Korea

  • Southeast Asia

  • India

  • Rest of Asia

  • South America

  • Brazil

  • Argentina

  • Rest of South America

  • Middle East & Africa

  • Turkey

  • Israel

  • Saudi Arabia

  • UAE

  • Rest of Middle East & Africa


Competitor Analysis

The report also provides analysis of leading market participants including:


  • Key companies Recombinant Protein Drug R & D revenues in global market, 2018-2023 (estimated), ($ millions)

  • Key companies Recombinant Protein Drug R & D revenues share in global market, 2022 (%)


Further, the report presents profiles of competitors in the market, key players include:


  • Eli Lilly

  • Novo Nordisk

  • Amgen

  • Merck

  • Sanofi

  • Pfizer

  • Roche

  • Gensci

  • Ankebio

  • United Cell

  • Sinobioway Hygene

  • Kexing

  • Dongbao

  • 3sbio

  • Gan&Lee

  • Hengrui


Outline of Major Chapters:

Chapter 1: Introduces the definition of Recombinant Protein Drug R & D, market overview.

Chapter 2: Global Recombinant Protein Drug R & D market size in revenue.

Chapter 3: Detailed analysis of Recombinant Protein Drug R & D company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Recombinant Protein Drug R & D in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 8: The main points and conclusions of the report.

Table of content

1 Introduction to Research & Analysis Reports1.1 Recombinant Protein Drug R & D Market Definition1.2 Market Segments1.2.1 Market by Type1.2.2 Market by Application1.3 Global Recombinant Protein Drug R & D Market Overview1.4 Features & Benefits of This Report1.5 Methodology & Sources of Information1.5.1 Research Methodology1.5.2 Research Process1.5.3 Base Year1.5.4 Report Assumptions & Caveats2 Global Recombinant Protein Drug R & D Overall Market Size2.1 Global Recombinant Protein Drug R & D Market Size: 2022 VS 20302.2 Global Recombinant Protein Drug R & D Market Size, Prospects & Forecasts: 2018-20302.3 Key Market Trends, Opportunity, Drivers and Restraints2.3.1 Market Opportunities & Trends2.3.2 Market Drivers2.3.3 Market Restraints3 Company Landscape3.1 Top Recombinant Protein Drug R & D Players in Global Market3.2 Top Global Recombinant Protein Drug R & D Companies Ranked by Revenue3.3 Global Recombinant Protein Drug R & D Revenue by Companies3.4 Top 3 and Top 5 Recombinant Protein Drug R & D Companies in Global Market, by Revenue in 20223.5 Global Companies Recombinant Protein Drug R & D Product Type3.6 Tier 1, Tier 2 and Tier 3 Recombinant Protein Drug R & D Players in Global Market3.6.1 List of Global Tier 1 Recombinant Protein Drug R & D Companies3.6.2 List of Global Tier 2

0 views0 comments

Recent Posts

See All

Comentarios


bottom of page